breast cancer and semaglutide A 30% Risk Reduction Sounds Big. The Actual Numbers Tell a Different Story. A new study says GLP-1 drugs lower risk. The real difference? Less than 1 percentage point. Read Daniel Flora: Weight-Loss Drugs and

BPC-157 has shown promise in addressing musculoskeletal injuries, gastrointestinal issues like inflammatory bowel disease, wound healing, pain management, and even neurological conditions

Given India's significant role in the generic pharmaceutical market, this development is expected to be positively received by manufacturers, healthcare providers, and patients

Safety depends entirely on the pharmacy's adherence to quality standards

Speciation of nickel in a hyperaccumulating plant by high-performance liquid chromatography-inductively coupled plasma mass spectrometry and electrospray MS/MS assisted by cloning using yeast complementation